Table 5.
Univariate |
Multivariate |
|||
P value | RR (95%CI) | P value | RR (95%CI) | |
Sex | 0.153 | 2.043 (0.768-5.438) | ||
Age | 0.502 | 0.987 (0.951-1.025) | ||
Stage | 0.196 | 1.562 (0.795-3.070) | ||
BCLC | 0.782 | 0.942 (0.615-1.441) | ||
Size | 0.830 | 1.010 (0.926-1.101) | ||
PVT | 0.988 | 0.994 (0.465-2.125) | ||
LN metastasis | 0.936 | 0.952 (0.289-3.141) | ||
Multiplicity | 0.622 | 1.197 (0.586-2.448) | ||
AFP | 0.034 | 1.001 (1.000-1.003) | 0.034 | 1.001 (1.000-1.003) |
PIVKA-II | 0.449 | 1.016 (0.976-1.057) | ||
Pre-RT treatment | 0.878 | 1.057 (0.520-2.147) | ||
Baseline IL-1 | 0.725 | 1.005 (0.977-1.034) | ||
Baseline IL-6 | 0.529 | 1.002 (0.996-1.007) | ||
Baseline IL-8 | 0.546 | 1.001 (0.999-1.003) | ||
Baseline IL-10 | 0.309 | 1.062 (0.946-1.193) | ||
Baseline IL-12 | 0.726 | 1.009 (0.962-1.058) | ||
Baseline TNF-α | 0.956 | 1.002 (0.942-1.066) |
Age, size, AFP, PIVKA-II, and baseline cytokine levels were analyzed as continuous variables using the Cox hazard ratio model. BCLC: Barcelona Clinic Liver Cancer; PVT: Portal vein thrombosis; LN: Lymph node; AFP: α-fetoprotein; PIVKA-II: Prothrombin induced by vitamin K absence-II; RT: Radiotherapy; IL: Interleukin; TNF: Tumor necrosis factor.